Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19)

An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030944

Enrollment

Unknown

Registered

2020-03-18

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased

Control group:current clinical treatment of SNCP

Eligibility

Sex/Gender

All

Age

4 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients are eligible for inclusion if they meet all of the following criteria within 5-7 days after the first admission to the ICU. 2. The patients met the diagnostic criteria of 2019-nCoV pneumonia (new coronavirus infection) pneumonia treatment plan (Fifth version), the National Health Office [2020] No.103.; 3. The primary disease is 2019 nCoV infection; 4. Respiratory distress, RP >=30 times/unit; 5. Under resting state, blood oxygen saturation <=93%; 6. PaO2 / FiO2 <=300nnhg (1mmhg = 0.133kpa); 7. Imaging data suggest bilateral lesions 8. Volunteer to participate in clinical research, understand and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. sNCP caused by other non-viral infections (such as trauma); 2. WHO grade III or IV pulmonary hypertension; 3. Malignant tumor in lung and other systems; 4. Lactating women or screening women with positive blood pregnancy test; 5. Idiopathic IgA deficiency; 6. Recent cardiovascular and cerebrovascular events (3 months); 7. Lung transplanted patients; 8. HIV positive patients; 9. According to the researcher's judgment, these subjects will be excluded because of some causes, such as any disease, treatment, or laboratory abnormal history or current evidence, which may confound the results of the study, interfere with the subject's participation in the study procedure, or be not in the best interest of the subject's participation in the study.

Design outcomes

Primary

Measure	Time frame
Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;	—

Countries

China

Contacts

Public ContactYe Xiaoqun

The Second Affiliated Hospital of Nanchang University

511201663@qq.com+86 0791 86300047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026